| 规格: | 98% |
| 分子量: | 268.7 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
Background:
Dazoxiben is a potent and orally active thromboxane (TX) synthase inhibitor[1].
Dazoxiben inhibits TXB2 production in clotting human whole blood with an IC50 of 0.3 μM and causes parallel enhancement of PGE2 greater than PGF2 alpha greater than 6-keto-PGF1 alpha production[1].Dazoxiben inhibits TXB2 production in rat kidney glomeruli with an IC50 of 1.60 μM) than in rat whole blood (IC50= 0.32μM), and is not associated with changes in PGE2, PGF2 alpha and 6-keto-PGF1 alpha production[1].
Dazoxiben (intraperitoneal administration; 100 μg/kg) produces a marked prolongation of the tail bleeding time with 96.8 ± 10.8 secs[2].
[1]. Patrignani P, et al. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism.J Pharmacol Exp Ther. 1984 Feb;228(2):472-7. [2]. Yu SM, et al. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.Br J Pharmacol. 1994 Mar;111(3):906-12.
m.cnreagent.com